Tim Urban is an author, speaker, and popular blogger best known for his blog, "Wait But Why." He is renowned for his engaging long-form articles and stick-figure illustrations that cover a wide range of topics, from procrastination to artificial intelligence. Tim graduated cum laude from Harvard University with a degree in Government and has co-founded several successful ventures, including ArborBridge and truePrep. His unique blend of humor and insight has earned him a large following and recognition as one of the internet's most captivating writers.

Andrew Brack is a distinguished scientist and entrepreneur, currently serving as the Program Manager for Proactive Health at ARPA-H. He previously co-founded Arrive Bio, a biotechnology company that uses machine learning to identify drugs for age-related diseases. Andrew has a Ph.D. in molecular biology and biophysics from King’s College London and has held faculty positions at UCSF and Stanford University. His research focuses on the cellular and molecular mechanisms of skeletal muscle repair during aging.

We are the first generation who won’t die.

Aubrey de Grey is a biomedical gerontologist and pioneering advocate for the science of aging. He is the President and Chief Science Officer of the Longevity Escape Velocity (LEV) Foundation, an organization dedicated to accelerating the development of rejuvenation biotechnologies. Aubrey is internationally recognized for formulating the SENS (Strategies for Engineered Negligible Senescence) framework—a comprehensive roadmap for repairing the cellular and molecular damage that drives aging. Trained in computer science and later earning a Ph.D. in biology from the University of Cambridge, Aubrey has spent over two decades promoting the idea that aging is a medical condition that can be treated. His scientific and advocacy work has reshaped public and academic discourse around longevity, inspiring a global movement of researchers, investors, and biohackers. Through the LEV Foundation and other initiatives, Aubrey continues to push forward research that aims not merely to slow aging but to reverse its effects—bringing the dream of radically extended healthy lifespan closer to reality.

Kristen Fortney is the co-founder and CEO of BioAge Labs, a computational biology startup in Berkeley, California. She received her PhD in Medical Biophysics from the University of Toronto and completed her postdoctoral training at Stanford University. Kristen is an expert in developing bioinformatics approaches to investigate aging and age-related diseases. Her research focuses on computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity. As CEO, she leads BioAge Labs in its mission to develop therapies that target aging to increase healthspan and address chronic diseases.

Matt Kaeberlein, PhD, is the CEO of Optispan, driving innovation in predictive, preventive, and personalized healthcare. A renowned expert in aging biology, he is also a professor at the University of Washington, where he has made significant contributions to the field of oral health sciences, pathology, and genome sciences. Kaeberlein co-directs the Dog Aging Project and serves as CEO of the American Aging Association. His research on longevity and aging has earned international recognition, and he has been a leader in advancing medical solutions to extend healthy human lifespans.

Brian Kennedy is a scientist and entrepreneur, known for his significant contributions to the field of aging research. He has held leadership positions at several prominent institutions, including the Buck Institute for Research on Aging, where he served as President and CEO. Brian's work focuses on understanding the mechanisms of aging and developing interventions to promote healthy longevity. His research has been instrumental in advancing the field of biogerontology and has garnered widespread recognition.

Andrew Steele is a scientist, writer, and campaigner based in Berlin. He holds a PhD in physics from the University of Oxford and has transitioned to computational biology, focusing on aging research. Andrew is the author of "Ageless: The New Science of Getting Older Without Getting Old" and regularly contributes to major publications like the Wall Street Journal and WIRED. He is also a popular science presenter on television and YouTube, making complex scientific concepts accessible to a broad audience.

Jean Hebert is a distinguished scientist and entrepreneur, currently serving as a Program Manager at ARPA-H, where he focuses on health science futures. He previously held faculty positions at the Albert Einstein College of Medicine, specializing in genetics and neuroscience. Jean is the founder of BE Therapeutics, a company dedicated to reversing age-related damage to brain tissue. His research explores stem cell transplantation, neurodegeneration, and cortical health, aiming to develop regenerative therapies for aging tissues.

Morten Scheibye-Knudsen is an associate professor at the University of Copenhagen, where he leads the Scheibye-Knudsen Group. His research focuses on understanding the cellular and organismal consequences of DNA damage, with the goal of developing interventions to combat age-related diseases such as Alzheimer's and Parkinson's. Morten's work has shown that replenishing certain metabolites altered by DNA damage can influence the aging process in model organisms, suggesting potential therapeutic approaches for healthier aging.

Omri Amriav-Drory is a scientist and entrepreneur, currently serving as the General Partner at NFX Bio. He is the Founder and CEO of Renewal Bio, a company focused on developing innovative solutions in the field of biotechnology. Omri previously founded Genome Compiler, which was acquired by Twist Bioscience, and has played a pivotal role in scaling and investing in influential techbio companies. His unique blend of scientific expertise and entrepreneurial experience makes him a significant figure in the techbio industry.

Dr. Emil Kendziorra is the Founder and CEO of Tomorrow.Bio, a startup dedicated to advancing biostasis (cryonics) research and providing human cryopreservation services. He graduated summa cum laude from the University of Göttingen and has extensive experience in cancer research and entrepreneurship. Dr. Kendziorra has founded and led multiple tech and medical startups, including MedLanes and onFeedback. His vision is to build an organization that significantly contributes to the field of cryonics and promotes public awareness about its potential.

Matthew Scholz is the Founder and Chief Executive Officer of Oisín Biotechnologies, a company pioneering gene therapy to target senescent cells and combat age-related diseases. He previously co-founded Immusoft and has been instrumental in developing innovative biotechnological solutions. Matthew's work focuses on creating therapies that can extend healthy lifespan and improve quality of life. His vision and leadership in the field of biotechnology make him a significant figure in the quest for longevity and healthspan enhancement.

Laurence Ion is a longevity advocate, entrepreneur, and investor dedicated to bringing aging under medical control. As the Founding Steward and Strategy Advisor at VitaDAO, he focuses on funding aging research projects and spinning out longevity biotech startups. Laurence is also the Co-initiator of Vitalia.city, a decentralized city aimed at accelerating drug development, and a Core member at JellyfishDAO, where he helps create inspiring content about longevity. His work aims to extend healthy lifespans through innovative and collaborative approaches.

Laura Minquini is a longevity and women's health entrepreneur, known for her work in branding and luxury design. She has collaborated with prestigious companies such as Louis Vuitton, Apple, and Amazon. Laura is the founder of MYKIGAI, a discovery and recommendation platform for longevity, and the core lead of AthenaDAO, a decentralized collective funding women's health research. Her mission is to leverage her expertise to make science work for women, promoting healthier aging and well-being.

Matthew "Oki" O'Connor is the Co-CEO of Cyclarity Therapeutics, a company focused on developing treatments for cardiovascular diseases through innovative cyclodextrin technology. With a Ph.D. in Biochemistry and extensive research experience in aging and regenerative medicine, O'Connor has made significant contributions to the field. His work aims to eliminate toxic oxidized cholesterol, a major factor in atherosclerosis, and improve overall healthspan.

Ronjon Nag is a British-American inventor, entrepreneur, and educator, known for his pioneering work in mobile technology and artificial intelligence. He is the Founder and President of the R42 Group, a venture capital firm investing in AI and longevity companies, and an Adjunct Professor in Genetics at the Stanford School of Medicine. Ronjon has co-founded several successful companies, including Lexicus and Cellmania, and his innovations have been instrumental in advancing mobile technology. His work continues to focus on the intersection of AI and biology, aiming to create solutions for healthier aging.

Kevin Caldwell is the co-founder, President, and CEO of Ossium Health, a pioneering bioengineering company focused on creating the world's first bone marrow bank for transplants. With a background in physics and economics from MIT and a JD from Harvard Law School, Kevin has also worked as an Engagement Manager at McKinsey and a Senior Investment Associate at Bridgewater Associates. His diverse experience and dedication to improving human health through innovative solutions make him a significant figure in the biotech industry.

Mark Hamalainen is a visionary scientist and entrepreneur dedicated to extending human lifespan through innovative biotechnology. As the co-founder and co-executive director of the Longevity Biotech Fellowship, he focuses on fostering a community of researchers and innovators working on breakthrough technologies to combat aging. His career has spanned from manual bench work in academia to lab automation at Synthego, and now to building the longevity movement. Mark is passionate about finding higher leverage methods to accelerate progress in the field of longevity.

Alberto Aparicio is an Assistant Professor in the Department of Bioethics and Health Humanities. He completed postdoctoral fellowships at the Global Observatory for Genome Editing at Harvard University and the Alexander von Humboldt Biological Resources Research Institute in Colombia. Dr. Aparicio holds a PhD in Science and Technology Studies from University College London and an MPhil in Technology Policy from Cambridge University. With experience in policy, academia, consultancy, and government, his research focuses on the governance of emerging biotechnology and the societal implications of bioscience, including evolving attitudes toward life and technoscience.

Prof. Peter Lidsky is an expert in virology and genetics, with MS and PhD training from Moscow State University, focusing on virus-host interactions in Picornaviruses. He advanced his career at the University of Zurich, developing fluorescent imaging tools for Drosophila. At UCSF, Prof. Lidsky integrated his virology and genetics expertise, establishing a renowned research program. He is best known for developing the "pathogen control" hypothesis of aging, a pioneering framework that continues to shape his groundbreaking research on the intersection of aging, immunity, and pathogen dynamics.

Ethan Perlstein is a visionary scientist-entrepreneur dedicated to eradicating rare diseases. As Founder/CEO of Perlara PBC, the first biotech public benefit corporation, Ethan has pioneered healthspan-extending therapeutics and cures for rare metabolic disorders. He also leads Maggie's Pearl LLC, advancing precision medicines for ultra-rare conditions, and recently launched Curetopia, a groundbreaking DAO aiming to transform rare disease treatment through decentralized collaboration. With a PhD from Harvard and impactful roles at Princeton and the Reeve Foundation, Ethan blends innovation and leadership to redefine biotech’s role in global health.

Anar Isman is the co-founder and CEO of AgelessRx, a telemedicine platform dedicated to slowing down the aging process through scientifically-backed interventions. With a background in investment management, Anar transitioned to the field of longevity science driven by a desire to make a meaningful impact on human health. He believes in making cutting-edge longevity treatments accessible to everyone and is passionate about advancing the field to help people live healthier, longer lives.

Jun Axup is a biotechnologist and entrepreneur, currently serving as the Chief Operating Officer at E11 Bio, a non-profit focused on building high-throughput molecular tools to map the brain connectome. She previously held the position of Chief Science Officer and Partner at IndieBio, where she funded and advised over 160 companies working on improving human and planetary health. Jun holds a PhD in chemical biology from the Scripps Research Institute and has co-founded multiple startups in fields such as immuno-oncology, protein engineering, and lab automation robotics. Her passion for brain longevity and innovative biotechnological solutions drives her work.

James Arrowood is an entrepreneur, legal expert, and executive with extensive experience in the life extension and biotechnology sectors. He is the CEO of the Alcor Life Extension Foundation, where he has been instrumental in guiding the organization since 2015. James initially joined Alcor as outside General Counsel, helping navigate complex legal and business challenges. He has also served on the board of directors for a major local non-profit and as its public relations chair, contributing to his long-standing expertise in media and public relations. His work focuses on advancing Alcor’s mission and engaging with the wider conversation on cutting-edge technologies aimed at extending human lifespan.

Dr Jack Scannell is best known for his work to diagnose the causes of the progressive decline in R&D productivity in the drug and biotechnology industry. He coined the term “Eroom’s Law” (from computer science’s “Moore’s Law” spelled backwards) to describe the contrast between falling biopharma R&D output efficiency since 1950 in the face of spectacular gains in basic science and in the brute force efficiency of the scientific activities on which drug discovery is generally believed to depend. His work has considered the contributions of scientific, economic, regulatory, and organisational factors. Recently, he has focused on the predictive validity of screening and disease models in drug R&D, which constitute perhaps the major productivity bottleneck. Dr Scannell is currently the CEO of Etheros Pharmaceuticals Corp. Etheros is developing small molecule enzyme mimetics, based on fullerene chemistry, for age-related and neurodegenerative diseases. He is an Associate of the Department of Science, Technology, and Innovation Studies at Edinburgh University. He led Discovery Biology at e-Therapeutics PLC, an Oxford-based biotech firm. He has experience in drug and biotech investment at UBS and at Sanford Bernstein where he ran the European Healthcare teams. He has a Ph.D. in neuroscience from Oxford University and a degree in medical sciences from Cambridge University.

Nathan Price is a scientist and entrepreneur with extensive experience in systems biology and biomedical research. He is the Chief Scientific Officer at Thorne and the Co-Director of the Center for Human Healthspan and Professor at the Buck Institute for Research on Aging. Nathan’s work focuses on leveraging multi-omics data, AI, and personalized health strategies to optimize human longevity and disease prevention. His research spans computational biology, precision medicine, and the development of interventions to promote healthy aging. Through his leadership in both academia and industry, he aims to transform healthcare by advancing science-driven approaches to longevity and well-being.

Xiaoxi Wei is an entrepreneur, scientist, and inventor specializing in biomimetic nanoscience and biopreservation for regenerative medicine. She is the founder and CEO of X-Therma, a pioneering company developing breakthrough ice prevention technologies to enable organ preservation and transplantation. With a vision to make "on-demand organs" a reality, Xiaoxi has dedicated her career to advancing cryopreservation and regenerative medicine. Her scientific expertise lies in supramolecular assembly and biomimetic chemistry. A recognized leader in her field, Xiaoxi has served as a healthcare advisor for the UC Regents Working Group on Innovation Transfer and Entrepreneurship, a scientific advisor to the Life Extension Foundation, and Vice Chair of the Younger Chemists Committee of the American Chemical Society. As a distinguished member of the RULEBREAKER Society in Germany, she continues to push the boundaries of science and innovation to revolutionize organ transplantation and regenerative medicine.

Jonathan Anomaly works with a company that offers embryo selection for polygenic traits. Before this, he was a professor who taught classes at Duke, Penn and UNC Chapel Hill. He co-authored Philosophy, Politics, and Economics (Oxford University Press, 2015), and more recently published Creating Future People: The Science and Ethics of Genetic Enhancement (Routledge, 2024).

Léo Pio-Lopez is a scientist specializing in artificial intelligence, computational biology, and regenerative medicine. He currently serves as an Affiliate Senior Scientist at the Allen Discovery Center at Tufts University, working within Michael Levin's laboratory. His interdisciplinary research integrates AI, cognitive science, and developmental biology to uncover fundamental mechanisms of regeneration, morphogenesis, aging, and cognitive processes across multiple biological scales. With deep expertise in computational biology, deep learning, drug discovery, and bioinformatics, Léo is at the cutting edge of AI-driven approaches to understanding aging and creating targeted therapies. His work aims to harness interdisciplinary strategies to develop innovative solutions for regenerative medicine and promote healthy longevity.

Michael Andregg builds tech to solve fundamental human challenges and expand life's flourishing across our lightcone. He founded Halcyon, which, developed high-speed, mass-producible electron microscopes and built a "molecular threader" to manipulate single DNA strands aiming at lowering the cost of DNA sequencing. He then founded Fathom, aiming at optical computing and high-bandwidth communication between chips and large memory inference for training AI at scale, now aiming at robotics. Currently, Michael leads Eon, which is developing human emulation technology for scanning people at the cell level to run high-fidelity emulations on cloud GPUs. This tech will help humanity avoid x-risks and gives solid state direct edit access to our own minds and bodies.

‍

​Sukhjit Takhar is a physician and entrepreneur with over two decades of experience in medical practice and healthcare innovation. He is the Co-Founder and Chief Medical Officer of PrimaryMD, a concierge primary care practice committed to delivering personalized and proactive healthcare services. Dr. Takhar holds board certifications in Internal Medicine, Emergency Medicine, and Infectious Disease, having completed his medical degree in 1999. He pursued residencies in Internal Medicine and Emergency Medicine, followed by a fellowship in Infectious Disease at UCLA David Geffen School of Medicine. His professional journey includes serving as an Associate Clinical Professor of Emergency Medicine at UCSF Fresno. Dr. Takhar's work focuses on integrating advanced diagnostics, preventive strategies, and lifestyle interventions to enhance patient health outcomes and longevity.

​Joshua Johnson is an Associate Professor at the University of Colorado Anschutz Medical Campus, specializing in reproductive biology and ovarian physiology. He leads a research laboratory within the Divisions of Reproductive Sciences and Reproductive Endocrinology and Infertility, focusing on mechanisms that drive ovarian aging and dysfunction. His research is dedicated to understanding the control of oocyte number within the ovary, particularly mechanisms that support oocyte quality and those leading to oocyte loss due to aging or premature ovarian failure. Dr. Johnson's work aims to identify women at risk of ovarian dysfunction and develop interventions to protect fertility and ovarian function. In addition to his research, Dr. Johnson contributes to medical education, directing reproductive sciences teaching for early-year medical students. He has received recognition for his work, including the Rogerio Lobo Award from the Society for Reproductive Investigation in 2021. Through his work, Dr. Johnson strives to advance our understanding of ovarian biology to improve women's reproductive health.

Dr. Amy B. Killen is a physician, entrepreneur, and regenerative medicine expert with over a decade of experience at the forefront of anti-aging and preventative health. She is the Co-Founder and Chief Medical Officer at Humanaut Health, a tech-enabled longevity clinic franchise launching in 2024, where she integrates cutting-edge therapies to optimize healthspan and human performance. Originally trained and board-certified in emergency medicine, Dr. Killen transitioned into longevity medicine after witnessing firsthand the toll of chronic disease in traditional healthcare settings. In her clinical practice, Dr Killen and her colleague, Dr Harry Adelson, pioneered the Full Body Stem Cell Makeover, one of the most innovative regenerative procedures currently available. Dr. Killen is also the founder of the Human Optimization Project (HOP), a dynamic longevity supplement system and educational platform, and a co-founder of Reputable Health, a Web3 platform for incentivized, AI-guided self-experimentation.

Dr. Bonnie EJ Maven is the founder and CEO of Vertility Health, an early-stage biotech committed to making genetic disease prevention accessible to all parents. Growing up on a small farm in Texas, Bonnie first discovered her passion for biology. She later moved to California to earn her PhD in Developmental Biology from UCSF and Gladstone Institutes. Today, she leads a dedicated team developing cutting-edge sperm-based technologies to empower families with more reproductive options.

Patrick House is a neuroscientist and author with a Ph.D. from Stanford University, where he studied under Dr. Robert Sapolsky. His doctoral research focused on Toxoplasma gondii, a protozoan parasite known for altering the behavior of its hosts. Transitioning from laboratory research to writing, House authored Nineteen Ways of Looking at Consciousness (St. Martin’s Press, 2022) and writes on AI, science, and culture for The New Yorker. He also spent three years at the neurotechnology startup Kernel, which develops non-invasive fNIRS technology. Through his work, House seeks to deepen our understanding of the mind and the narratives that shape human experience.

Masataka Watanabe is an associate professor in the Department of Systems Innovation at the University of Tokyo's Graduate School of Engineering. He specializes in theoretical and experimental neuroscience with a focus on consciousness. His research focuses on unraveling the neural mechanisms of consciousness, with particular emphasis on machine consciousness, spiking neural networks, brain-machine interfaces, and mind-uploading. In 2022, Watanabe authored "From Biological to Artificial Consciousness: Neuroscientific Insights and Progress,". This book approaches the problem of emergent consciousness through scientific studies that shed light on the neural mechanism of consciousness, and furthermore, delves into the possibility of artificial consciousness, a phenomenon that may ultimately solve the mystery. The novel lays out a new and credible pathway to mind-uploading through a method to test machine consciousness and a theory hypothesizing that consciousness emerges from a neural algorithm.

​Noor Siddiqui is a computer scientist and entrepreneur pioneering the intersection of genomics and reproductive health. She is the founder and CEO of Orchid, a reproductive technology company that offers whole-genome embryo screening to help prospective parents assess and mitigate genetic risks for their future children. Orchid's platform sequences over 99% of an embryo's genome, providing insights into more than 1,200 conditions, including heart disease, cancer, and neurodevelopmental disorders. Noor's inspiration for Orchid stems from her personal experience; her mother has retinitis pigmentosa, a genetic condition leading to vision loss. This motivated her to develop tools that empower parents with information to make informed reproductive choices. Through Orchid, Noor aims to shift reproductive healthcare from reactive to proactive, offering parents the tools to reduce genetic risks and promote healthier outcomes for future generations.​

Carolina Reis Oliveira is a biotechnology entrepreneur and scientist with a background in stem cell biology, tissue engineering, and immunology. She is the Co-founder and CEO of OneSkin, a Silicon Valley-based company developing topical products aimed at promoting skin health and longevity. Under her leadership, OneSkin has developed OS-01, a proprietary peptide designed to target cellular senescence, a key factor in skin aging. Through OneSkin, Carolina aims to develop interventions that address the root causes of aging, with a focus on maintaining skin health as a component of overall longevity.

​William Matthews is an entrepreneur and technologist with over a decade of experience in business development, operations, and compliance. He is the founder and CEO of Fellow, a men's health startup offering at-home semen analysis, vasectomy testing, and cryopreservation services. Under his leadership, Fellow developed the first FDA-validated, mail-in semen analysis kit, enabling men to assess their fertility conveniently and privately. The company operates the largest semen analysis lab in the U.S., serving both consumers and healthcare providers nationwide.

Steve Bacich is a veteran innovator and executive in the medical device industry with over two decades of experience leading advancements in reproductive and women’s health technologies. He currently serves as President and Chief Operating Officer of NEXT Life Sciences, a pioneering company developing Plan A™, a long-acting, reversible, non-hormonal male contraceptive aimed at transforming global reproductive options. He holds leadership roles across multiple ventures, including Chief Innovation Officer and Board Member at CrossBay Medical. Steve is also the CTO and Founding Partner of MED1 Ventures, a product development fund focused on high-impact ophthalmology and women’s health devices. MED1’s unique approach develops products—not companies—accelerating exits while minimizing investment risk.

​Jarod Rutledge is a scientist and investor with expertise in biotechnology, aging research, and neurodegenerative disease. He serves as Director of Biotechnology and Life Sciences at Starbloom Capital, where he leads investments in over twenty five companies advancing healthspan and longevity with a hundred million capital deployed. Jarod also holds the position of Biomarkers Lead at the Amaranth Foundation, which has funded dozens of high impact research projects and FROs with over fifty million in capital. Jarod earned his Ph.D. in neuroscience and systems biology from Stanford University and conducted postdoctoral research at the European Molecular Biology Laboratory (EMBL). His academic work includes being the first author on a paper in Nature developing the first truly organ-specific aging clocks with plasma proteomics.

Kenneth Lou is a serial entrepreneur with a background in business administration. He is the co-founder and CEO of Mito Health, a health-tech startup that offers AI-powered personalized health plans based on comprehensive bloodwork analysis. Mito Health aims to provide accessible, preventative healthcare solutions to help individuals live healthier, longer lives. Kenneth holds a Bachelor of Business Administration with a minor in Technopreneurship from the National University of Singapore. He participated in the NUS Overseas Colleges program, studying Information Technology. Through his ventures, Kenneth aims to leverage technology to address significant challenges in health and finance, striving to make impactful contributions to society.